169,962 research outputs found
ODB- Reasoner: un ambiente per la verifica di schemi e l’ottimizzazione di interrogazioni in OODB
S.Miniato. Atti a cura di Fausto Rabitti et al
A Matter of Time. Digital-Financial Consumers' Vulnerability in the Retail Payments Market
This Article aims to conceptualize the figure of the digital-financial payment consumer, which combines two separate - and ex se relevant - sources of vulnerability: digital vulnerability and financial vulnerability
Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man.
BACKGROUND:
Measurement of chromogranin A (CgA) levels in blood can be used to monitor neuroendocrine tumors (NETs). CgA levels may also be elevated in several other endocrine and non-endocrine diseases. It is well known that drugs affecting acid gastric secretion can increase gastrin. Proton-pump inhibitors are extensively used but only a few data have been reported on their effects on CgA secretion.
DESIGN:
The aim of the study was to evaluate the short-term effect of low dosages of omeprazole (OM) on CgA levels and to sensitize endocrinologists to possible false positive values of CgA in order to prevent expensive diagnostic work-up in searching for NETs.
SUBJECTS AND METHODS:
Thirty-five female and nine male in-patients (18-81 years) were studied. Mild or severe hypertension in 20 patients needed therapy. Endocrine and metabolic diseases were diagnosed in the majority of patients. CgA levels were evaluated before and during OM therapy (10 mg/day, orally).
RESULTS:
Without OM therapy, CgA levels were 64+/-6 microg/l. Elevated baseline CgA levels were found in nine subjects. CgA levels were significantly related to age (P<0.001), creatinine levels (P=0.03) and the severity of hypertension (P=0.002). On short-term OM therapy (n=42; 18.8+/-2.4 days; range 5-90 days) a significant (P<0.001) increase in CgA (145+/-22 microg/l) from baseline (63+/-7 microg/l) levels was found. The average net CgA increase on short-term OM therapy was 93+/-20 microg/l. There was a significant correlation between baseline CgA levels and CgA increase on short-term OM therapy (P=0.004) but not between the increase in CgA and the duration of the therapy.
CONCLUSIONS:
An increase in CgA levels quickly follows the start of low dosages of OM. This release is more pronounced when the baseline CgA levels are already increased by slight renal insufficiency or severe hypertension. In this common clinical situation an intensive work-up for NETs is not justified before reassessment of CgA after the withdrawal of OM
La nozione di controllo come fattispecie rilevante nelle concentrazioni
L'articolo esamina le interferenze esterne che nel corso degli ultimi anni hanno influenzato e contribuito a modificare la nozione di controllo contenuta nella disciplina delle operazioni di concentrazione ai sensi della normativa antitrust italiana
A mediator-based approach for integrating heterogeneous multimedia sources
In many applications, the information required by the user cannot be found in just one source, but has to be retrieved from many varying sources. This is true not only of formatted data in database management systems, but also of textual documents and multimedia data, such as images and videos. We propose a mediator system that provides the end-user with a single query interface to an integrated view of multiple heterogeneous data sources. We exploit the capabilities of the MOMIS integration system and the MILOS multimedia data management system. Each multimedia source is managed by an instance of MILOS, in which a collection of multimedia records is made accessible by means of similarity searches employing the query-by-example paradigm. MOMIS provides an integrated virtual view of the underlying multimedia sources, thus offering unified multimedia access services. Two features are that MILOS is flexible—it is not tied to any particular similarity function—and the MOMIS’s mediator query processor only exploits the ranks of the local answers
Reliability of short-term follow-up for assessing bioprosthetic heart valve performancE
[No abstract available
- …
